Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 8/20 | 0.34 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.33 |
| ▸ | THRA | P10827 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664789 | 0.63 | THRA (0.46) | THRBTHRAPLA2G2DPDE4APDE4B | |
| SCHEMBL2417435 | 0.61 | ESR2 (0.61) | ESR1ESR2 | |
| SCHEMBL12968236 | 0.60 | SMN1; SMN2 (0.41) | THRBESR1THRAHTR2C | |
| SCHEMBL31156940 | 0.60 | KDM4E (0.44) | — | |
| SCHEMBL27491980 | 0.59 | ALDH1A1 (0.38) | THRBTHRACNR2PLA2G2D | |
| SCHEMBL2506385 | 0.59 | PTPN1 (0.37) | THRBTHRACNR2 | |
| SCHEMBL8930859 | 0.58 | ALDH1A1 (0.40) | THRBESR1THRACNR2PLA2G2D | |
| SCHEMBL8930873 | 0.58 | ALDH1A1 (0.40) | THRBESR1THRACNR2PLA2G2D | |
| SCHEMBL8930868 | 0.58 | ALDH1A1 (0.40) | THRBESR1THRACNR2PLA2G2D | |
| SCHEMBL27509087 | 0.58 | ALDH1A1 (0.40) | THRBESR1THRACNR2PLA2G2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137192-A1 | Estrogen receptor modulators | PARKER DANN R JR (US) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137192-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | THRB 439/4885ESR1 5/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.